ARM
Arm today announced the appointment of new Board members Karen Dykstra, former Chief Financial and Administrative Officer of AOL and Jeff Sine, Co-Founder and Partner of Raine Group, effective immediately. These highly qualified leaders bring a diverse range of expertise to Arm as the company prepares for a potential public listing.
Arm Chief Executive Officer (CEO) Rene Haas said: “I extend a warm welcome to Karen and Jeff, both exceptional business leaders who will bring a depth and breadth of experience to the Arm Board.”
Arm also today announced the appointment of Jason Child as Chief Financial Officer (CFO). Child has more than 30 years of experience in leadership at high growth companies and scaling global finance functions. Child will join Arm on November 2, 2022 and lead the company’s global finance and IT organizations, reporting to Haas.
Haas added, “Jason is an experienced leader in global finance and technology. His extensive experience in financial management at public companies and IPO execution will be invaluable in preparation for a potential public listing. I look forward to working with him as part of the Arm leadership team as we continue to define the future of computing, built on Arm.”
Child will replace current CFO Inder Singh who will remain at Arm in an advisory role and assist in the transition through November before moving to a new opportunity.
Haas said, “I’d like to thank Inder for his contributions and leadership over these past few years. He has helped the company navigate many changes since joining in 2019, including building a strong organization with upgraded systems and processes in the finance, IT and cybersecurity teams. We wish him all the best moving forward.”
Child most recently served as senior vice president and CFO at Splunk from 2019. Prior to Splunk, Child held multiple CFO positions including at Groupon, which he helped to take public in 2011 and as CFO at Amazon International.
“Since its founding, Arm has had an incredible history of innovation and leadership in the semi-conductor industry,” said Child. “Arm is a world-class, category leader and I am thrilled to join as CFO during this exciting time for the company.”
About Karen Dykstra
Ms. Dykstra previously served as Chief Financial and Administrative Officer of AOL, a web portal and online service provider. Prior to AOL, she was a Partner at Plainfield Asset Management, and served as Chief Operating Officer and Chief Financial Officer of Plainfield Direct, Plainfield’s business development company. She previously spent over 25 years with Automatic Data Processing (ADP), a provider of human capital management solutions to employers, serving most recently as Chief Financial Officer. Ms. Dykstra is currently a director on the boards of VMware and Gartner, and has also served on the boards of Boston Properties, Crane and AOL.
About Jeff Sine
Mr. Sine is the Co-Founder and Partner of The Raine Group, a global merchant bank focused on technology, media and communications. Prior to founding Raine, he served as Vice Chairman and Global Head of Technology, Media & Telecom Investment Banking at UBS Investment Bank, was a Managing Director at Morgan Stanley and was an attorney at Sullivan & Cromwell in New York and London. Mr. Sine currently serves on the boards of many Raine portfolio companies and subsidiaries. He also serves on the boards of National Public Radio (NPR) (Vice-Chair), ITHAKA, Educational Testing Service (ETS) (Chair), American University and The Manhattan Theatre Club.
About Jason Child
Jason Child’s career spans 30 years across all aspects of global finance and strategy, accounting, capital markets/treasury, IPO execution and investor relations. He has extensive experience in scaling disruptive technologies within enterprise software/SaaS, e-commerce, local commerce, consumer hardware/IOT, and online residential real estate. He most recently served as senior vice-president and CFO at Splunk, a technology company specializing in application management, security and compliance, as well as business and web analytics. Before his executive leadership roles, Jason spent more than 11 years leading various global finance teams at Amazon, and served as CFO of Amazon International. Jason has served as a member of the board of directors of Coupang, Inc., an e-commerce company, since April 2022. He holds B.A. from the Foster School of Business at the University of Washington, where he currently serves on the Global Advisory Board.
About Arm
Arm technology is defining the future of computing. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 230 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, we are enabling artificial intelligence to work everywhere, and in cybersecurity, we are delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.
All information is provided "as is" and without warranty or representation. This document may be shared freely, attributed and unmodified. Arm is a registered trademark of Arm Limited (or its subsidiaries). All brands or product names are the property of their respective holders. © 1995-2022 Arm Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005775/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom